

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

B1

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07D 211/14, A61K 31/445, C07D 401/04, 413/04, 417/04, 211/46, 211/30, 235/30, 295/12, 239/42, 277/82, 263/58, 409/12, A61K 31/4427, 31/496, A61P 25/00</p>	A1	<p>(11) International Publication Number: WO 00/56712</p> <p>(43) International Publication Date: 28 September 2000 (28.09.00)</p>
<p>(21) International Application Number: PCT/EP00/02267</p> <p>(22) International Filing Date: 14 March 2000 (14.03.00)</p> <p>(30) Priority Data: 9906624.3 23 March 1999 (23.03.99) GB</p> <p>(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): LOVELL, Peter, John [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park south, Third Avenue, Harlow, Essex CM19 5AW (GB).</p> <p>(74) Agent: WATERS, David, Martin; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</p>		<p>(81) Designated States: AB, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: SULFONAMIDE DERIVATIVES AS 5-HT₇ RECEPTOR ANTAGONISTS</p> <div style="text-align: center; margin: 20px 0;"> <p style="margin-left: 600px;">(I)</p> </div> <p>(57) Abstract</p> <p>The invention relates to novel sulfonamide compounds of formula (I) having 5-HT₇ receptor antagonist activity, processes for their preparation, to compositions containing them and their use in the treatment of CNS and other disorders.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SULFONAMIDE DERIVATIVES AS 5-HT₇ RECEPTOR ANTAGONISTS

This invention relates to novel sulfonamide compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.

WO 97/29097, WO 98/48681 and WO 97/49695 all disclose a series of sulfonamide derivatives that are 5-HT₇ receptor antagonists and are useful in the treatment of various CNS diseases. Malleron et al (J. Med. Chem., 1993, 36, 1194-1202) discloses a series of indole derivatives that are claimed to act as potent and selective serotonin uptake inhibitors.

A structurally novel class of compounds has now been found which also possess 5-HT₇ receptor antagonist activity. The present invention therefore provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

Q is phenyl or thienyl;

R¹ is halogen, hydroxy, C₁₋₆alkyl, CF₃, OCF₃ or C₁₋₆alkoxy;

m is 0, 1, 2 or 3;

R² is C₁₋₄alkyl;

X is nitrogen, carbon or CH,

— is a single bond when X is nitrogen or CH or

== is a double bond when X is carbon;

D is a single bond, C=O, O or CH₂ subject to the proviso that when X is nitrogen then D is not oxygen;

P is phenyl, naphthyl, a 5 or 6 membered heteroaryl ring containing 1 to 3

heteroatoms selected from oxygen, nitrogen and sulphur, or a benzofused heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;

R³ is C₁₋₆alkyl optionally substituted by NR⁴R⁵, aryl, arylC₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, cyano, hydroxy, nitro, halogen, CF₃, C₂F₅, NR⁴R⁵, CONR⁴R⁵,

NR⁴COR⁵, S(O)_pNR⁴R⁵, CHO, OCF₃, SCF₃, CH₂OR⁶, CO₂R⁶ or COR⁶ where p

is 0, 1 or 2 and R⁴, R⁵ and R⁶ are independently hydrogen, C₁₋₆alkyl, aryl or arylC₁₋₆alkyl;

n is 0, 1, 2 or 3.

5 Alkyl groups whether alone or as part of another group may be straight chain or branched. The term 'halogen' is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine. The term 'aryl' is used herein to describe, unless otherwise stated, a group such as phenyl or naphthyl optionally substituted by one or more C₁₋₆alkyl or halogen. The term 'naphthyl' is
10 used herein to denote, unless otherwise stated, both naphthalen-1-yl and naphthalen-2-yl groups.

When Q is thienyl a preferred group is thien-2-yl. Preferably Q is phenyl.

When m is 1, R¹ is preferably halogen (particularly fluorine or chlorine), a C₁₋₆alkyl group (particularly methyl, ethyl, isopropyl or t-butyl), CF₃ or C₁₋₆alkoxy
15 group (particularly methoxy or ethoxy). When m is 2 or 3 the groups R¹ may be the same or different.

When Q = phenyl and m = 1 preferred examples include moieties in which R¹ is either a fluoro group with a para relationship with respect to the sulfonamide group or is a methyl group with a meta relationship with respect to the sulfonamide
20 linkage. When Q = phenyl and m = 2 preferred examples include those in which the R¹ groups are independently halogen or C₁₋₆alkyl substituted at the 2, 3 or 2, 4 positions with respect to the sulfonamide linkage. When Q = phenyl and m = 3 preferred examples include those in which the R¹ groups are independently halogen (particularly chloro), C₁₋₆alkyl (particularly methyl) or CF₃ substituted at the 2, 4
25 and 5 positions with respect to the sulfonamide linkage.

Suitable examples of R² groups include methyl, ethyl, isopropyl or n-butyl. Preferably R² is methyl or isopropyl, most preferably isopropyl.

Preferably X is nitrogen or CH such that --- is a single bond. Most preferably X is CH.

30 Preferably D is a single bond.

When P is a 5 or 6 membered heteroaryl ring suitable examples include thienyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrrolidinyl and pyrazinyl.

When P is a benzofused heteroaryl ring suitable examples include indolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinolinyl and isoquinolinyl. The
35 heterocyclic groups listed above can be linked to the remainder of the molecule via a carbon atom or, when present, a suitable nitrogen atom. It will be appreciated however, that when D is O then the heteroaryl ring must be linked to the rest of the

molecule via a carbon atom. Preferably P is phenyl, naphthyl, pyrimidin-2-yl or is a benzofused heteroaryl ring selected from the group consisting of quinolin-4-yl, 2-oxo-2,3-dihydrobenzimidazol-1-yl, 2-oxo-2,3-dihydrobenzaxazol-1-yl, indol-3-yl, indol-2-yl, benzoxazol-2-yl, benzothiazol-2-yl and particularly benzimidazol-2-yl.

- 5 When n is 1, R³ is preferably halogen (particularly fluorine or chlorine), a C₁₋₆alkyl optionally substituted by NR⁴R⁵ (particularly methyl), hydroxy, CF₃, C₁₋₆alkoxy (particularly methoxy) or groups COR⁶ or CO₂R⁶ in which R⁶ is methyl. When n is 2 or 3 the groups R³ may be the same or different. Preferably n is 0 or 1.

- 10 Particularly preferred compounds of the invention include:
 N-(2-(4-(1*H*-Benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-3, N-dimethyl benzene sulfonamide,
 3, 4 Dichloro-N-(2-(4-(1*H*-indol-3-yl)-piperidin-1-yl)-ethyl)-N-methyl-benzene sulfonamide,
 15 2,4,5-Trichloro-N-ethyl-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-benzene sulfonamide,
 2,4,5-Trichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-isopropyl benzene sulfonamide,
 4-Chloro-2,5-dimethyl-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-isopropyl benzene sulfonamide,
 20 N-(2-(4-(1*H*-Benzimidazol-2-yl)-piperazin-1-yl)-ethyl)-2,4,5-trichloro-N-isopropyl-benzene-sulfonamide,
 3, N-Dimethyl-N-(2-(4-(2-methyl-1*H*-indol-3-yl)-3, 6 dihydro-2*H*-pyridin-1-yl)-ethyl)-benzene sulfonamide,
 25 4-Fluoro-(N-(2-(4-(2-oxo-2,3-dihydro-benzimidazol-1-yl) 3,6-dihydro-2*H*-pyridin-1-yl)-ethyl)-benzene sulfonamide,
 2,3,4-Trichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-methyl-benzene-sulfonamide,
 2,5-Dibromo-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-methyl-benzene-sulfonamide,
 30 2,4-Dichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-5, N-dimethyl-benzene-sulfonamide,
 4, 5-Dichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-methyl-2-trifluoromethyl-benzenesulfonamide,
 35 2-Chloro-4-fluoro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-methyl-benzene-sulfonamide,
 N-(2-(4-(1*H*-Benzimidazol-2-yl)-piperazin-1-yl)-ethyl)-3,N-dimethyl benzene sulfonamide,

N-2-(4-(1*H*-Benzimidazol-2-yl)-piperazin-1-yl)-ethyl)-2,4,5-trichloro-N-methylbenzenesulfonamide,

2,4,5-Trichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperazin-1-yl)-ethyl)-N-methyl benzene sulfonamide,

5 4-Fluoro-N-(2-(4-(2-methoxyphenyl)-piperazin-1-yl)-ethyl)-N-methyl benzene sulfonamide

N-{2-[4-(1*H*-Benzimidazol-2-yl)-piperazin-1-yl]-ethyl}-2,4-dichloro-5,*N*-dimethylbenzenesulfonamide

or a pharmaceutically acceptable salt thereof


10 Other preferred compounds of this invention include those shown in Tables 1 - 5 below.

The compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, 15 hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.

Compounds of formula (I) may also form solvates such as hydrates, and the invention also extends to these forms. When referred to herein, it is understood that the term 'compound of formula (I)' also includes these forms.

20 Certain compounds of formula (I) are capable of existing in stereoisomeric forms including diastereomers and enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates. The different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis. The 25 invention also extends to any tautomeric forms and mixtures thereof.


The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises coupling a compound of formula (II):



(II)

in which Q, R¹, R² and m are as defined in formula (I) and Y is a leaving group with a compound of formula (III):

35



(III)

in which --- , X, D, P, n and R^3 are as defined in formula (I);
and optionally thereafter if appropriate:

- 5 • removing any protecting groups;
- forming a pharmaceutically acceptable salt.

Suitable leaving groups Y include halogen (particularly chloro) and
-OSO₂Ar groups such as tosylate. The reaction of a compounds of formulae (II) and
10 (III) is preferably carried out in a solvent such as acetonitrile or dichloromethane
optionally in the presence of sodium iodide and a base such as potassium carbonate.

Those skilled in the art will appreciate that it may be necessary to protect
certain groups. Suitable protecting groups and methods for their attachment and
removal are conventional in the art of organic chemistry, such as those described in
15 Greene T.W. 'Protective groups in organic synthesis' New York, Wiley (1981).

Compounds of formulae (II) and (III) are either commercially available or are
prepared using methods described herein or analogous to known methods.

Pharmaceutically acceptable salts may be prepared conventionally by
reaction with the appropriate acid or acid derivative.

20

Compounds of formula (I) and their pharmaceutically acceptable salts have
5-HT₇ receptor antagonist activity and are believed to be of potential use for the
treatment or prophylaxis of certain CNS disorders such as anxiety, depression, sleep
disorders (including disturbances of Circadian rhythms), migraine, Parkinson's
25 disease, schizophrenia, pain, appetite disorders and other indications such as
inflammation, spastic colon, renal disorders, hypotension, cardiovascular shock,
stroke, septic shock and gastrointestinal diseases such as IBS (irritable bowel
syndrome).

Thus the invention also provides a compound of formula (I) or a
30 pharmaceutically acceptable salt or a solvate thereof, for use as a therapeutic
substance, in particular in the treatment or prophylaxis of the above disorders. In
particular the invention provides a compound of formula (I) or a pharmaceutically
acceptable salt thereof or a solvate thereof for use in the treatment or prophylaxis of
depression, migraine and/or sleep disorders.

In another aspect the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt or a solvate thereof, for the manufacture of a medicament for the treatment or prophylaxis of the above disorders.

5 The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or a solvate thereof.

10 The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form
15 of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.

Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting
20 lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid
25 preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile
30 vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the
35 stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can

be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.

The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.5 to 100 mg; and such therapy may extend for a number of weeks or months.

When administered in accordance with the invention, no unacceptable toxicological effects are expected with the compounds of the invention.

The following Descriptions and Examples illustrate the preparation of the compounds of the invention.

20 Description 1

Toluene-3-sulfonic acid 2-(methyl-(toluene-3-sulfonyl)-amino)-ethyl ester (D1)

To a solution of 2-methylaminoethanol (1.0g, 13mmol) and diisopropylethylamine (5.8ml, 33mmol) in dichloromethane (50ml) at room temperature was added 3-methylphenylsulfonyl chloride (5.6g, 29mmol). The solution was heated to reflux under argon for 12 hours then cooled and partitioned between saturated aqueous sodium bicarbonate and dichloromethane. The organic phase was dried over sodium sulfate and concentrated *in vacuo*. The residue was purified by silica gel chromatography to afford the title compound (2.5g, 50%).

¹H NMR (CDCl₃) 7.69 (2H, m), 7.55 (2H, m), 7.47 (2H, m), 7.40 (2H, m), 4.19 (2H, t, 5.6Hz), 3.33 (2H, t, 5.6Hz), 2.78 (3H, s), 2.46 (3H, s), 2.43 (3H, s).

Description 2

4-Fluorobenzenesulfonic acid 2-((4-fluorobenzenesulfonyl)-methyl-amino)-ethyl ester (D2)

The title compound was prepared from 2-methylamino ethanol and 4-fluorophenyl sulfonyl chloride using the method described in Description 1.

¹H NMR (CDCl₃) 7.96 (2H, m), 7.80 (2H, m), 7.26 (4H, m), 4.21 (2H, t, 5.6Hz), 3.34 (2H, t, 5.6Hz), 2.79 (3H, s).

Description 3

3,4-Dichlorobenzenesulfonic acid 2-((3,4-dichlorobenzenesulfonyl)-methyl-amino)-ethyl ester (D3)

- 5 The title compound was prepared from 2-methylamino ethanol and 3,4 dichlorophenyl sulfonylchloride using the method described in Description 1.

¹H NMR (CDCl₃) 7.86 (1H, m), 7.80 (1H, m), 7.67-7.54 (4H, m), 4.19 (1H, m), 4.37 (1H, m), 3.33 (2H, m), 2.83 (3H, s).

10 **Description 4**

2,4,5-Trichlorobenzenesulfonic acid 2-(methyl -(2,4,5-trichlorobenzenesulfonyl) - amino)-ethyl ester (D4)

The title compound was prepared from 2-methylamino ethanol and 2,4,5 trichlorophenylsulfonylchloride using the method described in Description 1.

- 15 ¹H NMR (DMSO-d₆) 8.11 (1H, s), 8.07 (1H, s), 8.05 (1H, s), 7.82 (1H, s), 4.15 (1H, m), 3.71 (1H, m), 3.51 (2H, m), 2.89 (3H, s).

Description 5

2,4,5-Trichloro-N-ethyl-N-(2-hydroxyethyl)-benzene sulfonamide (D5)

- 20 The title compound was prepared from 2-ethylamino ethanol and 2,4,5 trichlorophenylsulfonylchloride using the method described in Description 1.

¹H NMR (CDCl₃) 8.20 (1H, s), 7.63 (1H, s), 3.78 (2H, q, 5.5Hz), 3.49 (4H, m), 1.93 (1H, t, 5.6Hz), 1.16 (3H, t, 7.1Hz).

25 **Description 6**

Methane sulfonic acid 2-(ethyl-(2,4,5-trichloro-benzenesulfonyl)-amino) ethyl ester (D6)

- 30 A solution of D5 (1.2g, 3.6mmol) and methanesulfonyl chloride (0.31mL, 4mmol) in triethylamine (0.75mL, 5.4mmol) and dichloromethane (25mL) was stirred at room temperature for 4hrs. The reaction mixture was washed with saturated aqueous sodium bicarbonate, the organic phase dried over sodium sulfate and concentrated *in vacuo* to afford the title compound which was used in subsequent preparations without further purification. MH⁺ 410/412/414/416.

35 **Description 7**

2,4,5-Trichloro-N-(2-chloroethyl)-N-isopropyl benzene sulfonamide (D7)

The title compound was prepared from 2-isopropylamino ethanol and 2,4,5 trichlorophenylsulfonylchloride using the method described in Description 1.

¹H NMR (CDCl₃) 8.22 (1H, s), 7.63 (1H, s), 3.96 (1H, m), 3.61 (4H, m), 1.16 (6H, d, 6.7Hz).

Description 8

- 5 **4-Chloro 2,5-dimethylbenzenesulfonic acid 2-(isopropyl -(4-chloro 2,5-dimethylbenzenesulfonyl) -amino)-ethyl ester (D8)**

The title compound was prepared from 2-isopropylamino ethanol and 4-chloro 2,5-dimethylphenylsulfonylchloride using the method described in Description 1. ¹H NMR (DMSO-d₆) 8.16 (1H, s), 8.11 (1H, s), 3.80 (2H, t, 5.6Hz), 3.60 (2H, t, 5.6Hz),
10 2.90 (3H, s).

Description 9

- 2,3,4-Trichloro-N-(2-chloroethyl)-N-methyl benzene sulfonamide (D9)**

The title compound was prepared from 2-methylamino ethanol and 2,3,4 trichlorophenylsulfonylchloride using the method described in Description 1.
15

Description 10

- 2,5 Dibromo-N-(2-chloroethyl)-N-methyl benzene sulfonamide (D10)**

The title compound was prepared from 2-methylamino ethanol and 2,5 dibromophenylsulfonylchloride using the method described in Description 1.
20

Description 11

- 2,4 Dichloro 5-methyl-N-(2-chloroethyl)-N-methyl benzene sulfonamide (D11)**

The title compound was prepared from 2-methylamino ethanol and 2,4-dichloro-5-methyl phenylsulfonylchloride using the method described in Description 1.
25

Description 12

- 4,5-Dichloro-N-(2-chloroethyl)-N-isopropyl-2-trifluoromethyl-benzenesulfonamide (D12)**

The title compound was prepared from 2-isopropylamino ethanol and 4,5-dichloro-2-trifluoromethyl-phenylsulfonyl chloride. MH⁺ 398/390/392/394.
30

Description 13

- 2-Chloro-4-fluoro-N-(2-chloroethyl)-N-methyl benzene sulfonamide (D13)**

The title compound was prepared from 2-methylamino ethanol and 2-chloro-5-fluoro-phenylsulfonylchloride using the method described in Description 1.
35

Description 14

4-(1*H*-Benzimidazol-2-yl)piperidine (D14)

A mixture of 4-piperidine carboxylic acid (5.30g, 40mmol), 1,2-diaminobenzene (4.32g, 40mmol) and polyphosphoric acid (40g) were heated to 190°C for 14 hours. Cooled, diluted with water (150ml) and basified with 50% KOH to pH 8. Solution cooled in an ice/salt bath to give a precipitate which was collected by filtration and washed with water. Solid dried in vacuo to afford the title compound (8.0g, 100%).
1H NMR (CDCl₃) 7.48 (2H, m), 7.09 (2H, m), 3.04 (2H, m), 2.92 (2H, m), 2.60 (2H, m), 2.55 (1H, m), 1.95 (2H, m), 1.71 (2H, m). MH⁺ 202.

10. Description 15**4-(4-Methyl-1*H*-benzimidazol-2-yl)piperidine (D15)**

The title compound was prepared from isonipecotic acid and 2,3 diamino toluene using the method described in Description 14. MH⁺ 216.

15. Description 16**4-(5-Methyl 1*H* benzimidazol-2-yl)piperidine (D16)**

The title compound was prepared from isonipecotic acid and 3,4 diamino toluene using the method described in Description 14. MH⁺ 216.

20. Description 17**4-(5-Fluoro 1*H* benzimidazol-2-yl)piperidine (D17)**

The title compound was prepared from isonipecotic acid and 2,3 diamino fluorobenzene using the method described in Description 14. MH⁺ 220.

25. Description 18**4-(5-Hydroxy 1*H* benzimidazol-2-yl)piperidine (D18)**

The title compound was prepared from isonipecotic acid and 3,4 diamino anisole using the method described in Description 14. MH⁺ 218.

30. Description 19**4-(Benzothiazol-2-yl)piperidine (D19)**

The title compound was prepared from isonipecotic acid and 2-aminothiophenol using the method described in Description 14. MH⁺ 219.

35. Description 20**4-(Benzoxazol-2-yl)piperidine (D20)**

The title compound was prepared from isonipecotic acid and 2-aminophenol using the method described in Description 14. MH⁺ 203.

Description 21**N-(2-(4-Benzylpiperazin-1-yl)-ethyl)-3,N-dimethyl benzene sulfonamide (D21)**

A solution of D1 (22g, 89mmol) and N-benzylpiperazine (15.7g, 89mmol) was heated to reflux in toluene for 96 hours. The reaction was cooled and concentrated *in vacuo*. The residue was partitioned between saturated aqueous sodium bicarbonate and dichloromethane. The organic phase was dried over sodium sulfate and concentrated *in vacuo* and the residue was purified by chromatography on silica gel to afford the title compound. MH^+ 388.

10

Description 22**3,N-Dimethyl-N-(2-piperazin-1-yl-ethyl)-benzene sulfonamide (D22)**

A solution of D21 (6g, 16mmol) in ethanol (50ml) and acetic acid (50ml) was hydrogenated over palladium on charcoal catalyst (600mg) for 72 hours. The catalyst was recovered by filtration, washed with ethanol and the combined organics concentrated *in vacuo* to afford the title compound. MH^+ 298.

15

Description 23**{2-[4-(1H-Benzimidazol-2-yl)-piperazin-1-yl]-ethyl}-methyl-amine hydrochloride salt (D23)**

20

A mixture of 2-piperazin-1-yl-1H-benzimidazole (0.7 g, 3.47 mmol), sodium iodide (0.79 g, 5.26 mmol), dry potassium carbonate (0.48 g, 3.5 mmol) and (2-chloro-ethyl)-methyl-amine hydrochloride salt (0.46 g, 3.56 mmol) in dimethylformamide was heated at 100°C for 1H under argon. Afterwards, a further amount of dry potassium carbonate (0.48 g, 3.5 mmol) and 1-chloro-2-(methylamino)ethane (0.46 g, 3.56 mmol) was added and the reaction mixture was heated at 100°C for another 4 h. The mixture was cooled to room temperature, the solid was filtered off, washed with dichloromethane. The combined filtrates were evaporated, the residue was partially dissolved in dichloromethane (70 ml), the solid was collected by filtration, washed with dichloromethane (2 x10 ml) and dried to give the product as an hydrochloride salt; yellowish solid (0.5 g, 49 %): MH^+ = 260.

25

30

Example 1**N-(2-(4-(1H-Benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-3, N-dimethyl benzene sulfonamide (E1)**

35


To a solution of D1 (192mg, 0.5mmol) in acetonitrile was added D14 (100mg, 0.5mmol), potassium carbonate (140mg, 1.0mmol) and catalytic sodium iodide (5mg).

- The reaction mixture was heated to reflux for 18 hours then cooled and concentrated *in vacuo*. After partitioning between saturated aqueous sodium bicarbonate and dichloromethane the organic phase was dried over sodium sulfate and concentrated *in vacuo*. The residue was purified by chromatography on silica gel to afford the title compound (49mg, 24%).

¹H NMR (CDCl₃) 7.58 (3H, m), 7.38 (2H, m), 7.19 (2H, m) 3.15 (2H, t, 6.7Hz), 2.90 (3H, m), 2.80 (3H, s), 2.56 (2H, t, 6.7Hz), 2.43 (3H, s), 2.15 (4H, m), 1.89 (2H, m).
MH⁺ 413

- 10 Examples E2 - 21 shown in Table 1 were prepared using a procedure similar to that described in example E1 using Toluene-3-sulfonic acid 2-(methyl-(toluene-3-sulfonyl)-amino)-ethyl ester (D1) and a 4-substituted piperidine.

Table 1




15

Example	R	MH ⁺
E2	Phenyl	373
E3	Benzyl	387
E4	1H-Indol-3-yl	412
E5	5-Methyl-1H-indol-3-yl	426
E6	5-Methoxy-1H-indol-3-yl	442
E7	5-Carbomethoxy-1H-indol-3-yl	470
E8	7-Methyl-1H-indol-3-yl	426
E9	4-Methyl-1H-benzimidazol-2-yl	427
E10	5-Methyl-1H-benzimidazol-2-yl	427
E11	5-Hydroxy-1H-benzimidazol-2-yl	429
E12	5-Fluoro-1H-benzimidazol-2-yl	431
E13	Benzoxazol-2-yl	414
E14	Benzothiazol-2-yl	430
E15	Naphthalen-1-yl	423
E16	Naphthalen-2-yl	423
E17	5-Chloro-1H-benzimidazol-2-yl	447/449
E18	5-Fluoro-benzoxazol-2-yl	432

E19	6-Fluoro-benzoxazol-2-yl	432
E20	6-Chloro, 5-fluoro-1 <i>H</i> -benzimidazol-2-yl	465/467
E21	1 <i>H</i> -Indol-2-yl	412

Examples E22 - 25 shown in Table 2 were prepared using a procedure similar to that described in example E1 using 4-fluorobenzenesulfonic acid 2-((4-fluorobenzenesulfonyl)-methyl-amino)-ethyl ester (D2) and a 4-substituted piperidine.

Table 2



Example	R	MH+
E22	Phenoxy	393
E23	Benzoyl	405
E24	2-oxo-2,3 dihydro benzimidazol-1-yl	433
E25	1 <i>H</i> -Indol-3-yl	416

10


Example 26

3, 4 Dichloro-N-(2-(4-(1*H*-indol-3-yl)-piperidin-1-yl)-ethyl)-N-methyl-benzene sulfonamide (E26)

The title compound was prepared using the procedure described in Example 1 using 3,4-dichlorobenzenesulfonic acid 2-((3,4-dichlorobenzenesulfonyl)-methyl-amino)-ethyl ester (D3) and a 4-(1*H*-indol-3-yl)-piperidine. MH+ 467.

15
20
Examples E27 and E28 shown in Table 3 were prepared using 2,4,5-Trichlorobenzene sulfonic acid 2-(methyl-(2,4,5-trichlorobenzenesulfonyl)-amino)-ethyl ester (D4) and a substituted piperidine.

Table 3



Example	R	MH+
E27	2-amino-benzoyl	504/506/508/510
E28	4-(5-fluoro-1 <i>H</i> -benzimidazol-2-yl)	519/521/523/525

Example 29

2,4,5-Trichloro-N-ethyl-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-benzene sulfonamide (E29)

The title compound was prepared using the procedure described in Example 1 using D6 and 4-(5-fluoro-1*H*-benzimidazol-2-yl)piperidine (D17). MH+ 533/535/537/539.

Example 30

2,4,5-Trichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-isopropyl benzene sulfonamide (E30)

The title compound was prepared using the procedure described in Example 1 using D7 and 4-(5-fluoro-1*H*-benzimidazol-2-yl)piperidine (D17). MH+ 547/549/551/553.

Example 31

4-Chloro-2,5-dimethyl-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-isopropyl benzene sulfonamide (E31)

The title compound was prepared using the procedure described in Example 1 using D8 and 4-(5-fluoro-1*H*-benzimidazol-2-yl)piperidine (D17). MH+ 507/509.

Example 32

N-(2-(4-(1*H*-Benzimidazol-2-yl)-piperazin-1-yl)-ethyl)-2,4,5-trichloro-N-isopropyl-benzene-sulfonamide (E32)

The title compound was prepared using the procedure described in Example 1 using D7 and 1-(1*H*-benzimidazol-2-yl)piperazine. MH+ 530/532/534/536.

Example 33

3, N-Dimethyl-N-(2-(4-(2-methyl-1*H*-indol-3-yl)-3, 6 dihydro-2*H*-pyridin-1-yl)-ethyl)-benzene sulfonamide (E33)

The title compound was prepared using the procedure described in Example 1 using toluene-3-sulfonic acid 2-(methyl-(toluene-3-sulfonyl)-amino)-ethyl ester (D1) and 2-methyl-3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1*H* indole. MH+ 424.

5 **Example 34**

4-Fluoro-N-(2-(4-(2-oxo-2,3-dihydro-benzimidazol-1-yl) 3,6-dihydro-2*H*-pyridin-1-yl)-ethyl)-benzene sulfonamide (E34)

The title compound was prepared using the procedure described in Example 1 using 4-fluorobenzenesulfonic acid 2-((4-fluorobenzenesulfonyl)-methyl-amino)-ethyl ester
10 (D2) and 1-(1,2,3,6-tetrahydro-pyridin-4-yl)-1,3-dihydro benzimidazol-2-one. MH+ 431.

Example 35

2,3,4-Trichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl-N-methyl-benzene-sulfonamide (E35)
15

The title compound was prepared using the procedure described in Example 1 using 2,3,4-Trichloro-N-(2-chloroethyl)-N-methyl benzene sulfonamide (D9) and 4-(5-fluoro 1*H* benzimidazol-2-yl)piperidine (D17). MH+ 519/521/523/525.

20 **Example 36**

2,5-Dibromo-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl-N-methyl-benzene-sulfonamide (E36)

The title compound was prepared using the procedure described in Example 1 using 2,5-Dibromo-N-(2-chloroethyl)-N-methyl benzene sulfonamide (D10) and 4-(5-fluoro
25 1*H* benzimidazol-2-yl)piperidine (D17). MH+ 573/575/577.

Example 37

2,4-Dichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl-5, N-dimethyl-benzene-sulfonamide (E37)

30 The title compound was prepared using the procedure described in Example 1 using 2,4 dichloro-N-(2-chloroethyl)-N-methyl benzene sulfonamide (D11) and 4-(5-fluoro 1*H* benzimidazol-2-yl)piperidine (D17). MH+ 499/501/503.

Example 38

35 **4, 5-Dichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-methyl-2-trifluoromethyl-benzenesulfonamide (E38)**

The title compound was prepared using the procedure described in Example 1 using 4,5-dichloro-N-(2-chloroethyl)-N-methyl-2-trifluoromethyl-benzenesulfonamide (D12) and 4-(5-fluoro 1H benzimidazol-2-yl)piperidine (D17). MH+ 581/583/585.

5 Example 39

2-Chloro-4-fluoro-N-(2-(4-(5-fluoro-1H-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-methyl-benzene-sulfonamide (E39)

The title compound was prepared using the procedure described in Example 1 using 2-chloro-4 fluoro-N-(2-chloroethyl)-N-methyl benzene sulfonamide (D13) and 4-(5-fluoro 1H benzimidazol-2-yl)piperidine (D17). MH+ 469/470.


Example 40

N-(2-(4-(1H-Benzimidazol-2-yl)-piperazin-1-yl)-ethyl)-3,N-dimethyl benzene sulfonamide (E40)

15 A solution of D22 (0.50g, 1.6mmol) and 2-chloro 1H benzimidazole (0.25g, 1.6mmol) in toluene were heated at reflux for 14 hours. On cooling, the solvent was removed *in vacuo* and the residue partitioned between saturated aqueous sodium bicarbonate and dichloromethane. The organics were dried over sodium sulfate and concentrated *in vacuo*. The residue was purified by chromatography on silica gel to afford the title compound (150mg, 22%) MH+ 414.

Examples E41 - 47 shown in Table 4 were prepared using the procedure similar to that described in example E1 using Toluene-3-sulfonic acid 2-(methyl-(toluene-3-sulfonyl)-amino)-ethyl ester (D1) and a N-substituted piperazine.

25 Table 4



Example	R	MH+
E41	2-Chlorophenyl	408/410
E42	3-Trifluoromethylphenyl	442
E43	Pyrimidin-2-yl	376
E44	5-Ethylpyrimidin-2-yl	404
E45	6-Chlorobenzothiazol-2-yl	465/467

E46	Benzoxazol-2-yl	415
E47	6-Chloroquinolin-4-yl	460

Example 48

N-2-(4-(1*H*-Benzimidazol-2-yl)-piperazin-1-yl)-ethyl)-2,4,5-trichloro-N-methylbenzenesulfonamide (E48)

- 5 The title compound was prepared using the procedure described on Example 1 using 2,4,5-Trichlorobenzenesulfonic acid 2-(methyl -(2,4,5-trichlorobenzenesulfonyl) - amino)-ethyl ester (D4) and 1-(1*H* benzimidazol-2-yl) piperazine. MH+ 502/504/506/508.

10 **Example 49**

2,4,5-Trichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperazin-1-yl)-ethyl)-N-methyl benzene sulfonamide (E49)

- The title compound was prepared using the procedure described in Example 1 using 2,4,5-Trichlorobenzenesulfonic acid 2-(methyl -(2,4,5-trichlorobenzenesulfonyl) - amino)-ethyl ester (D4) and 1-(5-fluoro-1*H* benzimidazol-2-yl) piperazine. MH+ 520/522/524/526.

Example 50

- 20 **4-Fluoro-N-(2-(4-(2-methoxyphenyl)-piperazin-1-yl)-ethyl)-N-methyl benzene sulfonamide (E50)**

The title compound was prepared using the procedure described in Example 1 using 4-fluorobenzenesulfonic acid 2-((4-fluorobenzenesulfonyl)-methyl-amino)-ethyl ester (D2) and 4-(2-methoxyphenyl)-piperazine. MH+ 408.

25 **Example 51**


N-{2-[4-(1*H*-Benzimidazol-2-yl)-piperazin-1-yl]-ethyl}-2,4-dichloro-5,*N*-dimethylbenzenesulfonamide (E51)

- A mixture of 2,4-dichloro-5-methylbenzenesulphonyl chloride (81 mg, 0.31 mmol), {2-[4-(1*H*-Benzimidazol-2-yl)-piperazin-1-yl]-ethyl}-methyl-amine hydrochloride salt (D23) (80 mg, 0.31 mmol) and pyridine (0.5 ml) in dry dichloromethane (5 ml) 30 was stirred at room temperature for 17h. The mixture was then diluted with dichloromethane (30 ml), washed with aqueous sodium bicarbonate (1x10ml) and dried.(MgSO₄). The solvent was evaporated and the residue was co-evaporated with toluene (5 ml). Column chromatography of the residue (eluting with methanol-

dichloromethane gradient) gave the product as a yellowish solid (25 mg, 17%); MS: m/z (MH^+) = 482.

5 Examples E52 - 58 shown in Table 5 were prepared using a procedure similar to that described in example E51 using D23 and a substituted aromatic sulfonyl chloride

Table 5



Example	Ar	MH+
E52	4-Bromo-5-chloro thiophen-2-yl	518/520/522
E53	2,4 dichloro 5-methylphenyl	482/484/486
E54	4-bromo 2,5 difluorophenyl	514/516
E55	5-chloro 2-methoxyphenyl	464/466
E56	2-ethyl 4-bromophenyl	506/508
E57	4-bromo 2-trifluoromethoxyphenyl	562/564
E58	2-chloro 4-fluorophenyl	452/454

10


Pharmacological Testing

15 $[^3H]$ -5-Carboxamidotryptamine binding to human 5-HT₇ receptor clones expressed in 293 cells *in vitro*.

The affinity of the compounds of this invention for the 5-HT₇ receptor binding site can be determined by methods described in WO 97/29097. All compounds tested had a pK_i in the range 6.2 - 9.0. Examples E28 - 31, E37 and E38 had a pK_i > 8.5.

Claims:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

- Q is phenyl or thienyl;
 R^1 is halogen, hydroxy, C_{1-6} alkyl, CF_3 , OCF_3 or C_{1-6} alkoxy;
 m is 0, 1, 2 or 3;
 R^2 is C_{1-4} alkyl;
 X is nitrogen, carbon or CH,
 --- is a single bond when X is nitrogen or CH or
 = is a double bond when X is carbon,
 D is a single bond, $C=O$, O or CH_2 subject to the proviso that when X is nitrogen then D is not oxygen;
 P is phenyl, naphthyl, a 5 or 6 membered heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur, or a benzofused heteroaryl ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur;
 R^3 is C_{1-6} alkyl optionally substituted by NR^4R^5 , aryl, aryl C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, cyano, hydroxy, nitro, halogen, CF_3 , C_2F_5 , NR^4R^5 , $CONR^4R^5$, NR^4COR^5 , $S(O)_pNR^4R^5$, CHO , OCF_3 , SCF_3 , CH_2OR^6 , CO_2R^6 or COR^6 where p is 0, 1 or 2 and R^4 , R^5 and R^6 are independently hydrogen, C_{1-6} alkyl, aryl or aryl C_{1-6} alkyl;
 n is 0, 1, 2 or 3.

2. A compound according to claim 1 in which Q is phenyl.
3. A compound according to claim 1 or claim 2 in which R^2 is methyl or isopropyl.
4. A compound according to any one of the preceding claims in which X is nitrogen or a CH group.

5. A compound according to any one of the preceding claims in which P is benzimidazol-2-yl.


- 5 6. A compound according to claim 1 which is
 N-(2-(4-(1*H*-Benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-3, N-dimethyl benzene
 sulfonamide,
 3, 4 Dichloro-N-(2-(4-(1*H*-indol-3-yl)-piperidin-1-yl)-ethyl)-N-methyl-benzene
 sulfonamide,
 10 2,4,5-Trichloro-N-ethyl-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-
 benzene sulfonamide,
 2,4,5-Trichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-
 isopropyl benzene sulfonamide,
 4-Chloro-2,5-dimethyl-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-
 15 ethyl)-N-isopropyl benzene sulfonamide,
 N-(2-(4-(1*H*-Benzimidazol-2-yl)-piperazin-1-yl)-ethyl)-2,4,5-trichloro-N-isopropyl-
 benzene-sulfonamide,
 3, N-Dimethyl-N-(2-(4-(2-methyl-1*H*-indol-3-yl)-3, 6 dihydro-2*H*-pyridin-1-yl)-
 ethyl)-benzene sulfonamide,
 20 4-Fluoro-(N-(2-(4-(2-oxo-2,3-dihydro-benzimidazol-1-yl) 3,6-dihydro-2*H*-pyridin-1-
 yl)-ethyl)-benzene sulfonamide,
 2,3,4-Trichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-
 methyl-benzene-sulfonamide,
 2,5-Dibromo-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-
 25 methyl-benzene-sulfonamide,
 2,4-Dichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-5, N-
 dimethyl-benzene-sulfonamide,
 4, 5-Dichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-
 methyl-2-trifluoromethyl-benzenesulfonamide,
 30 2-Chloro-4-fluoro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperidin-1-yl)-ethyl)-N-
 methyl-benzene-sulfonamide,
 N-(2-(4-(1*H*-Benzimidazol-2-yl)-piperazin-1-yl)-ethyl)-3,N-dimethyl benzene
 sulfonamide,
 N-2-(4-(1*H*-Benzimidazol-2-yl)-piperazin-1-yl)-ethyl)-2,4,5-trichloro-N-methyl-
 35 benzenesulfonamide,
 2,4,5-Trichloro-N-(2-(4-(5-fluoro-1*H*-benzimidazol-2-yl)-piperazin-1-yl)-ethyl)-N-
 methyl benzene sulfonamide,

4-Fluoro-N-(2-(4-(2-methoxyphenyl)-piperazin-1-yl)-ethyl)-N-methyl benzene sulfonamide

N-{2-[4-(1*H*-Benzimidazol-2-yl)-piperazin-1-yl]-ethyl}-2,4-dichloro-5,*N*-dimethyl-benzenesulfonamide

5 or a pharmaceutically acceptable salt thereof


7. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises coupling a compound of formula (II):



10

(II)

in which Q, R¹, R² and m are as defined in formula (I) and Y is a leaving group with a compound of formula (III):



15

(III)

in which --- , X, D, P, n and R³ are as defined in formula (I); and optionally thereafter if appropriate:

- removing any protecting groups;
- forming a pharmaceutically acceptable salt.

20

8. A compound according to any one of claims 1 to 6 for use in therapy.

25

9. A compound according to any one of claims 1 to 6 for use in the treatment of CNS disorders.

10. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier or excipient.

30

INTERNATIONAL SEARCH REPORT

Int. onal Application No
PCT/EP 00/02267

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/14 A61K31/445 C07D401/04 C07D413/04 C07D417/04
C07D211/46 C07D211/30 C07D235/30 C07D295/12 C07D239/42
C07D277/82 C07D263/58 C07D409/12 A61K31/4427 A61K31/496

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 675 801 A (RHONE POULENC RORER SA) 30 October 1992 (1992-10-30) claims 1,9; example 17	1-4,8-10
X	WO 97 29097 A (SMITHKLINE BEECHAM PLC ;FORBES IAN THOMSON (GB)) 14 August 1997 (1997-08-14) cited in the application claim 1	1,8-10
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

19 July 2000

Date of mailing of the international search report

02/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/02267

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MALLERON J -L ET AL: "NEW INDOLE DERIVATIVES AS POTENT AND SELECTIVE SEROTONIN UPTAKE INHIBITORS" JOURNAL OF MEDICINAL CHEMISTRY, US, AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 36, no. 9, 1993, pages 1194-1202, XP000195950 ISSN: 0022-2623 cited in the application the whole document	1,8-10
A	WO 97 49695 A (FORBES IAN THOMSON ; RAHMAN SHIRLEY KATHERINE (GB); SMITHKLINE BEEC) 31 December 1997 (1997-12-31) cited in the application abstract	1,8-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

19 July 2000

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 00/02267

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2675801 A	30-10-1992	NONE	
WO 9729097 A	14-08-1997	EP 0883613 A JP 2000504677 T	16-12-1998 18-04-2000
WO 9749695 A	31-12-1997	EP 0912550 A US 6025367 A	06-05-1999 15-02-2000